The study has evaluated 494 adult patients with UC who had not responded well to conventional therapy, such as corticosteroids and/or immunosuppressants.
In the trial, 16.5% of the patients achieved clinical remission compared to 9.3% on placebo at week 8.
At week 52, 17.3% achieved clinical remission compared to 8.5% on placebo. These results were statistically significant compared to placebo.
Abbott Global Pharmaceutical Clinical Development vice president Eugene Sun said they are encouraged by these study results with Humira and the potential they may have for patients.